Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes.

Whilst the decision regarding defibrillator implantation in a patient with a familial sudden cardiac death syndrome is likely to be most significant for any particular individual, the clinical decision-making process itself is complex and requires interpretation and extrapolation of information from a number of different sources. This document provides recommendations for adult patients with the congenital Long QT syndromes, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy. Although these specific conditions differ in terms of clinical features and prognosis, it is possible and logical to take an approach to determining a threshold for implantable cardioveter-defibrillator implantation that is common to all of the familial sudden cardiac death syndromes based on estimates of absolute risk of sudden death.

[1]  Wojciech Zareba,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, European heart journal.

[2]  G. Bonsel,et al.  Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. , 2010, Europace.

[3]  M Borggrefe,et al.  Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome: Results From the FINGER Brugada Syndrome Registry , 2010, Circulation.

[4]  M. Ackerman,et al.  Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. , 2009, Heart rhythm.

[5]  P. Schwartz Cutting nerves and saving lives. , 2009, Heart rhythm.

[6]  A. Leenhardt,et al.  Incidence and Risk Factors of Arrhythmic Events in Catecholaminergic Polymorphic Ventricular Tachycardia , 2009, Circulation.

[7]  D. Roden,et al.  Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans , 2009, Nature Medicine.

[8]  E. W. Hancock,et al.  AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American , 2009, Journal of the American College of Cardiology.

[9]  E. W. Hancock,et al.  AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the , 2009, Journal of the American College of Cardiology.

[10]  B. Gersh,et al.  Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy , 2009, Heart.

[11]  E. W. Hancock,et al.  AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the , 2009, Circulation.

[12]  S. Priori,et al.  High Efficacy of β-Blockers in Long-QT Syndrome Type 1: Contribution of Noncompliance and QT-Prolonging Drugs to the Occurrence of β-Blocker Treatment “Failures” , 2009, Circulation.

[13]  C. Berul,et al.  Video-assisted thoracoscopic cardiac denervation: a potential novel therapeutic option for children with intractable ventricular arrhythmias. , 2008, The Annals of thoracic surgery.

[14]  J. Bourke,et al.  Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. , 2008, European heart journal.

[15]  S. Priori,et al.  Catecholaminergic polymorphic ventricular tachycardia. , 2008, Progress in cardiovascular diseases.

[16]  E. Kaufman,et al.  Risk of death in the long QT syndrome when a sibling has died. , 2008, Heart rhythm.

[17]  P. Schwartz,et al.  Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. , 2008, The New England journal of medicine.

[18]  Dan M. Roden,et al.  Clinical practice. Long-QT syndrome. , 2008, The New England journal of medicine.

[19]  Y. Yokoyama,et al.  Clinical Characteristics and Risk Stratification in Symptomatic and Asymptomatic Patients with Brugada Syndrome: Multicenter Study in Japan , 2007, Journal of cardiovascular electrophysiology.

[20]  Eloisa Arbustini,et al.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2007, European heart journal.

[21]  Lars Eckardt,et al.  Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. , 2007, European heart journal.

[22]  S. Viskin,et al.  Asymptomatic Brugada syndrome: a cardiac ticking time-bomb? , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[23]  P. Lambiase,et al.  Clinical indications for genetic testing in familial sudden cardiac death syndromes: an HRUK position statement , 2007, Heart.

[24]  Wojciech Zareba,et al.  Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome. , 2007, American heart journal.

[25]  H. Watkins,et al.  Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype. , 2007, Journal of the American College of Cardiology.

[26]  B. Maron,et al.  Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities in Competitive Athletes: 2007 Update: A Scientific Statement From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism Endorsed by the American College of Cardi , 2007, Circulation.

[27]  P. Brugada,et al.  Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. , 2007, European heart journal.

[28]  Derick R. Peterson,et al.  Long QT syndrome in adults. , 2007, Journal of the American College of Cardiology.

[29]  A. Krahn,et al.  Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. , 2006, Heart rhythm.

[30]  M. Silka,et al.  Pacemakers and implantable cardioverter-defibrillators in pediatric patients. , 2006, Heart rhythm.

[31]  M. Ackerman,et al.  Epinephrine QT stress testing in congenital long QT syndrome. , 2006, Journal of electrocardiology.

[32]  Michael J Ackerman,et al.  Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. , 2006, JAMA.

[33]  H. Garan,et al.  Sympathomimetic Infusion and Cardiac Repolarization: The Normative Effects of Epinephrine and Isoproterenol in Healthy Subjects , 2006, Journal of cardiovascular electrophysiology.

[34]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[35]  P. Elliott,et al.  Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. , 2006, European heart journal.

[36]  A. Camm,et al.  Delayed paced ventricular activation in the long QT syndrome is associated with ventricular fibrillation. , 2006, Heart rhythm.

[37]  J. A. Gomes,et al.  Risk Stratification of Individuals with the Brugada Electrocardiogram: A Meta‐Analysis , 2006, Journal of cardiovascular electrophysiology.

[38]  A. Wilde,et al.  Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients , 2005, Journal of Medical Genetics.

[39]  S. Russell,et al.  Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. , 2005, Heart rhythm.

[40]  W. Mckenna,et al.  Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy , 2005, Heart.

[41]  H. Watkins,et al.  The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[42]  Arthur J Moss,et al.  Long QT syndrome: from channels to cardiac arrhythmias. , 2005, The Journal of clinical investigation.

[43]  S. Priori,et al.  Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? , 2005, Circulation.

[44]  J. Brugada,et al.  Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? , 2005, Circulation.

[45]  P. Schwartz Management of long QT syndrome , 2005, Nature Clinical Practice Cardiovascular Medicine.

[46]  A. Tajik,et al.  Yield of genetic testing in hypertrophic cardiomyopathy. , 2005, Mayo Clinic proceedings.

[47]  C. Antzelevitch,et al.  Cellular Mechanisms Underlying the Development of Catecholaminergic Ventricular Tachycardia , 2005, Circulation.

[48]  G. Vincent,et al.  Risk assessment in long QT syndrome: the Achilles heel of appropriate treatment. , 2005, Heart rhythm.

[49]  G. Breithardt,et al.  Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. , 2005, Heart rhythm.

[50]  A. Proclemer,et al.  Brugada-like ECG abnormalities during thioridazine overdose. , 2005, British journal of clinical pharmacology.

[51]  S. Russell,et al.  Arrhythmogenic Right Ventricular Dysplasia: A United States Experience , 2005, Circulation.

[52]  N. Blom,et al.  Implantable cardioverter defibrillator implantation in children in The Netherlands , 2005, European Journal of Pediatrics.

[53]  B. Maron,et al.  Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[54]  G. Breithardt,et al.  Long-Term Prognosis of Individuals With Right Precordial ST-Segment–Elevation Brugada Syndrome , 2005, Circulation.

[55]  S. Sen-Chowdhry,et al.  Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management. , 2004, The American journal of medicine.

[56]  X. Jouven,et al.  Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2004, Circulation.

[57]  S. Priori,et al.  Association of Long QT Syndrome Loci and Cardiac Events Among Patients Treated With β-Blockers , 2004 .

[58]  B. Hainque,et al.  Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. , 2004, European heart journal.

[59]  M. Ackerman,et al.  β-Blocker Therapy Failures in Symptomatic Probands with Genotyped Long-QT Syndrome , 2004, Pediatric Cardiology.

[60]  T. Paul,et al.  High Incidence of Appropriate and Inappropriate ICD Therapies in Children and Adolescents with Implantable Cardioverter Defibrillator , 2004, Pacing and clinical electrophysiology : PACE.

[61]  S. Hughes The pathology of hypertrophic cardiomyopathy , 2004, Histopathology.

[62]  S. Priori,et al.  Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome , 2004, Circulation.

[63]  G. Breithardt,et al.  Implantable Cardioverter/Defibrillator Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy: Single-Center Experience of Long-Term Follow-Up and Complications in 60 Patients , 2004, Circulation.

[64]  K. Gauvreau,et al.  Psychosocial factors and quality of life in children and adolescents with implantable cardioverter-defibrillators. , 2004, The American journal of cardiology.

[65]  M. Block,et al.  Potential benefit from implantable cardioverter-defibrillator therapy in children and young adolescents , 2004, Heart.

[66]  John K Triedman,et al.  Implications of Implantable Cardioverter Defibrillator Therapy in Congenital Heart Disease and Pediatrics , 2004, Journal of cardiovascular electrophysiology.

[67]  M. Link,et al.  Implantable Cardioverter-Defibrillator Therapy for Prevention of Sudden Death in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2003, Circulation.

[68]  J. Brugada,et al.  Determinants of Sudden Cardiac Death in Individuals With the Electrocardiographic Pattern of Brugada Syndrome and No Previous Cardiac Arrest , 2003, Circulation.

[69]  C. Tracy,et al.  American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, European heart journal.

[70]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[71]  Carlo Napolitano,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[72]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[73]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[74]  J. Brugada,et al.  Natural History of Brugada Syndrome: , 2003, Journal of cardiovascular electrophysiology.

[75]  S. Viskin Implantable Cardioverter Defibrillator in High‐Risk Long QT Syndrome Patients , 2003, Journal of cardiovascular electrophysiology.

[76]  Iacopo Olivotto,et al.  Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[77]  M. Nagashima,et al.  Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death , 2003, Heart.

[78]  A. Wilde,et al.  Absence of Calsequestrin 2 Causes Severe Forms of Catecholaminergic Polymorphic Ventricular Tachycardia , 2002, Circulation research.

[79]  G. Breithardt,et al.  Electrophysiologic investigation in Brugada syndrome; yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. , 2002, European heart journal.

[80]  S. Priori,et al.  Programmed Electrical Stimulation in Brugada Syndrome: How Reproducible Are the Results? , 2002, Journal of cardiovascular electrophysiology.

[81]  Carlo Napolitano,et al.  Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia , 2002, Circulation.

[82]  S. Priori,et al.  Natural History of Brugada Syndrome: Insights for Risk Stratification and Management , 2002, Circulation.

[83]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[84]  K. Brown,et al.  Mutations of the Cardiac Ryanodine Receptor (RyR2) Gene in Familial Polymorphic Ventricular Tachycardia , 2001, Circulation.

[85]  S. Priori,et al.  Mutations in the Cardiac Ryanodine Receptor Gene (hRyR2) Underlie Catecholaminergic Polymorphic Ventricular Tachycardia , 2001, Circulation.

[86]  P. Asfar,et al.  Transient ST Segment Elevation in Right Precordial Leads Induced by Psychotropic Drugs: Relationship to the Brugada Syndrome , 2001, Journal of cardiovascular electrophysiology.

[87]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[88]  G. Danieli,et al.  Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. , 2000, Journal of the American College of Cardiology.

[89]  S. Priori,et al.  Clinical and Genetic Heterogeneity of Right Bundle Branch Block and ST-Segment Elevation Syndrome: A Prospective Evaluation of 52 Families , 2000, Circulation.

[90]  A J Moss,et al.  Spectrum of Mutations in Long-QT Syndrome Genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 , 2000, Circulation.

[91]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[92]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[93]  W. Allan,et al.  Long QT Syndrome , 1998, Pediatrics.

[94]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[95]  T. Riesenfeld,et al.  A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. , 1999, Journal of the American College of Cardiology.

[96]  P. Elliott,et al.  Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[97]  S. Priori,et al.  Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. , 1998, The New England journal of medicine.

[98]  S. Priori,et al.  Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. , 1998, Circulation.

[99]  J. Brugada,et al.  Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. , 1998, Circulation.

[100]  W. Mckenna,et al.  Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. , 1997, Circulation.

[101]  W. Mckenna,et al.  Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. , 1997, Heart.

[102]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[103]  Arthur J Moss,et al.  SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome , 1995, Cell.

[104]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[105]  P. Coumel,et al.  Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. , 1995, Circulation.

[106]  G. Thiene,et al.  Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. , 1994, British heart journal.

[107]  J. Brugada,et al.  Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. , 1992, Journal of the American College of Cardiology.

[108]  M. Leppert,et al.  The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. , 1992, The New England journal of medicine.

[109]  S. Epstein,et al.  Prognostic Determinants in Hypertrophic Cardiomyopathy: Prospective Evaluation of a Therapeutic Strategy Based on Clinical, Holter, Hemodynamic, and Electrophysiological Findings , 1992, Circulation.

[110]  G. Fontaine,et al.  [Right ventricular dysplasia]. , 1992, Annales de cardiologie et d'angeiologie.

[111]  J. Seidman,et al.  Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. , 1991, The New England journal of medicine.

[112]  A. Moss,et al.  The Long QT Syndrome: Prospective Longitudinal Study of 328 Families , 1991, Circulation.

[113]  M. Frenneaux,et al.  Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. , 1990, Circulation.

[114]  B. Maron,et al.  Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. , 1990, Journal of the American College of Cardiology.

[115]  M. Frenneaux,et al.  Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. , 1990, Journal of the American College of Cardiology.

[116]  D. Corrado,et al.  Right ventricular cardiomyopathy and sudden death in young people. , 1988, The New England journal of medicine.

[117]  W. Roberts,et al.  Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. , 1982, Circulation.

[118]  R Frank,et al.  Right Ventricular Dysplasia: A Report of 24 Adult Cases , 1982, Circulation.

[119]  G. R. Fitzgerald,et al.  Bidirectional tachycardia in a child. A study using His bundle electrography. , 1975, British heart journal.

[120]  P. Schwartz,et al.  All LQT3 patients need an ICD: true or false? , 2009, Heart rhythm.

[121]  Wataru Shimizu,et al.  Brugada syndrome: report of the second consensus conference. , 2005, Heart rhythm.

[122]  J. Towbin,et al.  Long-Term Follow-Up of Individuals With the Electrocardiographic Pattern of Right Bundle-Branch Block and ST-Segment Elevation in Precordial Leads V1 to V3 , 2002, Circulation.

[123]  G. Landes,et al.  Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias , 1996, Nature Genetics.

[124]  J. Mason,et al.  Electrophysiologic testing in patients with the long QT syndrome. , 1985, Circulation.

[125]  P. Coumel Catecholamine-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children : report of four cases , 1978 .